STOCK TITAN

Orasure Tech - OSUR STOCK NEWS

Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.

Overview of OraSure Technologies Inc. (NASDAQ: OSUR)

OraSure Technologies Inc., headquartered in Bethlehem, Pennsylvania, is a prominent innovator in the healthcare diagnostics industry. The company specializes in the development, manufacturing, and distribution of oral fluid diagnostic and sample collection devices, along with other advanced technologies designed to detect and diagnose critical medical conditions. Operating through two primary segments—Diagnostics and Molecular Solutions—OraSure serves a diverse range of customers, including clinical laboratories, hospitals, public health organizations, research institutions, pharmaceutical companies, and direct consumers.

Diagnostics Segment

The Diagnostics segment of OraSure focuses on producing rapid diagnostic tests and specimen collection devices that address infectious diseases such as HIV and HCV. Key products include the OraQuick® In-Home HIV Test, OraQuick® HCV Rapid Antibody Test, and the OraSure® HIV-1 Oral Specimen Collection Device. These solutions are designed to provide fast, reliable, and non-invasive testing, making them ideal for point-of-care and at-home use. Additionally, OraSure offers oral fluid testing solutions for drug abuse detection, including the Intercept® Oral Fluid Drug Testing System and Q.E.D.® Saliva Alcohol Test, which are widely used in workplace and clinical settings.

Molecular Solutions Segment

The Molecular Solutions segment is dedicated to providing innovative kits for the collection, stabilization, and transportation of genetic material samples. These kits are utilized in molecular testing for both hereditary conditions and infectious diseases, such as COVID-19. This segment has become a significant revenue driver for the company, with a strong customer base in the United States. OraSure’s molecular solutions are widely adopted in research, clinical diagnostics, and pharmaceutical applications, underscoring the company’s role in advancing personalized medicine and genomic research.

Cryosurgical Products

In addition to diagnostics, OraSure manufactures and distributes cryosurgical products, such as the Histofreezer®, which is used for the removal of common and plantar warts and other benign skin lesions. These products are marketed to healthcare professionals and are also available over-the-counter for consumer use, further diversifying the company’s product portfolio.

Competitive Position and Market Significance

OraSure Technologies differentiates itself through its proprietary oral fluid diagnostic technologies, which offer a unique combination of convenience, accuracy, and accessibility. The company operates in a competitive landscape that includes both traditional diagnostic methods and emerging technologies. However, its focus on non-invasive, rapid testing solutions positions it as a leader in point-of-care and at-home diagnostics. By addressing critical healthcare needs such as HIV testing and genetic sample collection, OraSure plays a vital role in improving public health outcomes and advancing medical research.

Customer Base and Applications

OraSure’s products are utilized across a wide spectrum of applications, including infectious disease testing, drug abuse detection, genetic research, and dermatological treatments. Their customer base spans clinical laboratories, hospitals, physician offices, public health organizations, government agencies, and research institutions. The company also reaches consumers directly through retail and online channels, further enhancing accessibility to its innovative solutions.

Challenges and Opportunities

While OraSure faces challenges such as regulatory compliance, competition from alternative diagnostic methods, and customer concentration risks, it also has significant opportunities for growth. The increasing demand for personalized medicine, the expansion of at-home diagnostic testing, and the global emphasis on public health initiatives provide a favorable environment for the company’s continued innovation and market expansion.

Conclusion

OraSure Technologies Inc. is a key player in the healthcare diagnostics industry, offering a diverse range of products that address critical medical needs. With its expertise in oral fluid diagnostics and molecular solutions, the company is well-positioned to continue delivering innovative, accessible, and reliable testing solutions to its global customer base.

Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) announces participation in investor conferences. Live webcasts and replays available on the company's investor relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
-
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) Announces Q3 GAAP EPS of $0.15 and Q3 Non-GAAP EPS of $0.27, Grows Cash Balance to $224.9M, Reports 7% Core Revenue Growth, and Provides Financial Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary
OraSure Technologies, Inc. has scheduled its regular earnings conference call for November 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
Rhea-AI Summary
OraSure Technologies, Inc. announces Q2 2023 financial results, with InteliSwab® test revenue of $47.5 million, a 10% YoY increase. Q2 core revenue grew 4% sequentially and 3% YoY. Cash balance increased to $185.9 million. InteliSwab® orders expected to generate at least $70 million in revenue in H2 2023. On track to achieve operating cash flow breakeven on core business by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.29%
Tags
none
-
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call for 5:00 pm ET on Thursday, August 3, 2023. A webcast of the conference call will be available on OraSure's website. The webcast will be archived for approximately 90 days. To participate in the live conference call, pre-registration is required.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
Rhea-AI Summary

OraSure Technologies reported Q4 2022 revenue of $123.1 million, a 94% increase year-over-year, driven by InteliSwab® sales of $88.9 million, up 12% sequentially. The company secured two federal contracts for InteliSwab® and partnered with Quest Diagnostics for saliva collection kits. Q4 GAAP EPS was $0.21, with Non-GAAP EPS at $0.36. A restructuring plan is expected to save $15 million annually, aiming for cash flow breakeven by end of 2024. Cash increased to $111 million. Notably, sales of COVID-19 kits declined by 98% year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.17%
Tags
none

FAQ

What is the current stock price of Orasure Tech (OSUR)?

The current stock price of Orasure Tech (OSUR) is $3.57 as of March 3, 2025.

What is the market cap of Orasure Tech (OSUR)?

The market cap of Orasure Tech (OSUR) is approximately 273.4M.

What does OraSure Technologies specialize in?

OraSure Technologies specializes in oral fluid diagnostic and sample collection devices, focusing on infectious diseases, genetic testing, and drug abuse detection.

What are the primary business segments of OraSure Technologies?

OraSure operates in two main segments: Diagnostics, which includes rapid tests for diseases like HIV and HCV, and Molecular Solutions, which provides kits for genetic sample collection and stabilization.

Who are the customers of OraSure Technologies?

OraSure’s customers include clinical laboratories, hospitals, public health organizations, research institutions, pharmaceutical companies, and direct consumers.

What makes OraSure’s products unique?

OraSure’s products are known for their non-invasive, rapid testing capabilities, leveraging proprietary oral fluid diagnostic technologies for convenience and accuracy.

What are some challenges faced by OraSure Technologies?

OraSure faces challenges such as regulatory compliance, competition from alternative diagnostic methods, and risks related to customer concentration.

What is the significance of OraSure’s molecular solutions segment?

The molecular solutions segment specializes in genetic sample collection kits, which are crucial for molecular testing in personalized medicine and infectious disease diagnostics.

What cryosurgical products does OraSure offer?

OraSure offers cryosurgical products like Histofreezer®, used for the removal of common and plantar warts and other benign skin lesions.

How does OraSure contribute to public health?

OraSure contributes to public health by providing accessible, reliable diagnostic solutions for critical conditions like HIV and HCV, improving early detection and treatment.

What industries does OraSure Technologies serve?

OraSure serves industries such as healthcare diagnostics, genetic research, pharmaceutical development, and public health initiatives.

How does OraSure compete in the diagnostics market?

OraSure competes by offering proprietary, non-invasive diagnostic solutions that emphasize convenience, accuracy, and accessibility, differentiating it from traditional methods.
Orasure Tech

Nasdaq:OSUR

OSUR Rankings

OSUR Stock Data

273.39M
72.00M
3.05%
90.64%
2.18%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
BETHLEHEM